Brian M. Hahn
Net Worth
Last updated:
What is Brian M. Hahn net worth?
The estimated net worth of Mr. Brian M. Hahn is at least $9,185,067 as of 18 Jun 2024. He owns shares worth $1,139,472 as insider, has earned $10,395 from insider trading and has received compensation worth at least $8,035,200 in GlycoMimetics, Inc..
What is the salary of Brian M. Hahn?
Mr. Brian M. Hahn salary is $803,520 per year as Senior Vice President & Chief Financial Officer in GlycoMimetics, Inc..
How old is Brian M. Hahn?
Mr. Brian M. Hahn is 51 years old, born in 1974.
What stocks does Brian M. Hahn currently own?
As insider, Mr. Brian M. Hahn owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| GlycoMimetics, Inc. (GLYC) | Senior Vice President & Chief Financial Officer | 70,643 | $16.13 | $1,139,472 |
What does GlycoMimetics, Inc. do?
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Brian M. Hahn insider trading
GlycoMimetics, Inc.
Mr. Brian M. Hahn has made 3 insider trades between 2015-2024, according to the Form 4 filled with the SEC. Most recently he purchased 17,500 units of GLYC stock worth $4,340 on 18 Jun 2024.
The largest trade he's ever made was exercising 20,000 units of GLYC stock on 11 Nov 2022. As of 18 Jun 2024 he still owns at least 70,643 units of GLYC stock.
GlycoMimetics key executives
GlycoMimetics, Inc. executives and other stock owners filed with the SEC:
- Mr. Brian M. Hahn (51) Senior Vice President & Chief Financial Officer